Gillespie Robinson & Grimm Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 234,887 shares of the company’s stock after selling 245 shares during the quarter. Johnson & Johnson makes up approximately 3.7% of Gillespie Robinson & Grimm Inc.’s investment portfolio, making the stock its 8th biggest holding. Gillespie Robinson & Grimm Inc.’s holdings in Johnson & Johnson were worth $30,390,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Ascent Wealth Partners LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $3,245,000. Archford Capital Strategies LLC boosted its holdings in Johnson & Johnson by 16.6% in the fourth quarter. Archford Capital Strategies LLC now owns 19,583 shares of the company’s stock valued at $2,527,000 after acquiring an additional 2,789 shares during the last quarter. Commonwealth Bank of Australia boosted its holdings in Johnson & Johnson by 73.3% in the fourth quarter. Commonwealth Bank of Australia now owns 389,167 shares of the company’s stock valued at $50,214,000 after acquiring an additional 164,605 shares during the last quarter. Capital Wealth Planning LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $3,159,000. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in shares of Johnson & Johnson by 8.4% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 1,081,192 shares of the company’s stock valued at $139,528,000 after purchasing an additional 84,120 shares during the last quarter. Hedge funds and other institutional investors own 72.01% of the company’s stock.
A number of equities research analysts have recently commented on JNJ shares. Bank of America reaffirmed a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Morgan Stanley reaffirmed an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target on the stock. in a research report on Thursday, July 18th. Finally, Raymond James cut their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $150.60.
NYSE JNJ traded up $0.15 on Thursday, hitting $129.37. 195,802 shares of the company were exchanged, compared to its average volume of 6,717,944. The company has a market cap of $351.43 billion, a PE ratio of 15.81, a PEG ratio of 2.25 and a beta of 0.69. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The stock has a fifty day moving average of $129.96 and a 200-day moving average of $135.03. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. Johnson & Johnson’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.10 earnings per share. On average, analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.94%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: How does a margin account work?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.